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Carriers of the fragile X premutation (PM) can develop a variety of early neurological
symptoms, including depression, anxiety and cognitive impairment as well as being
at risk for developing the late-onset fragile X-associated tremor/ataxia syndrome
(FXTAS). The absence of effective treatments for FXTAS underscores the importance
of developing efficacious therapies to reduce the neurological symptoms in elderly PM
carriers and FXTAS patients. A recent preliminary study reported that weekly infusions
of Allopregnanolone (Allop) may improve deficits in executive function, learning and
memory in FXTAS patients. Based on this study we examined whether Allop would
improve neurological function in the aged CGG knock-in (CGG KI) dutch mouse,
B6.129P2(Cg)-Fmr1tm2Cgr/Cgr, that models much of the symptomatology in PM carriers
and FXTAS patients. Wild type and CGG KI mice received 10 weekly injections of Allop
(10 mg/kg, s.c.), followed by a battery of behavioral tests of motor function, anxiety,
and repetitive behavior, and 5-bromo-2′-deoxyuridine (BrdU) labeling to examine adult
neurogenesis. The results provided evidence that Allop in CGG KI mice normalized
motor performance and reduced thigmotaxis in the open field, normalized repetitive
digging behavior in the marble burying test, but did not appear to increase adult
neurogenesis in the hippocampus. Considered together, these results support further
examination of Allop as a therapeutic strategy in patients with FXTAS.
Keywords: : FXTAS, allopregnanolone, mouse, behavior, adult neurogenesis
INTRODUCTION
Approximately 1.5 million individuals in the US are carriers of the Fragile X premutation (PM),
with prevalence estimates ranging from 1:209 to 1:250 in females and 1:430 to 1:800 in males
(Hunter et al., 2008; Hantash et al., 2011; Tassone et al., 2012). Many carriers develop neurological
and psychological problems over their lifespan including anxiety, depression, and poor motor
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performance (Aziz et al., 2003; Moore et al., 2004; Cornish
et al., 2005; Farzin et al., 2006; Coffey et al., 2008; Koldewyn
et al., 2008; Bourgeois et al., 2011; Goodrich-Hunsaker et al.,
2011). Carriers of PM are also at risk for developing Fragile
X-associated tremor/ataxia syndrome (FXTAS), a late onset
neurodegenerative disorder characterized by tremors, ataxia,
brain atrophy and cognitive decline (Hagerman et al., 2001).
The chances of developing FXTAS increase dramatically with
age, with approximately 40% of males and 8–11% of female
PM carriers over the age of 50 developing FXTAS (Rodriguez-
Revenga et al., 2009). Indeed, FXTAS may be one of the more
common causes of tremor/ataxia in older adults (Jacquemont
et al., 2004). Because of the dramatic increase in the number of
individuals reaching the age of 65, and increasing life expectancy,
the numbers of FXTAS patients will increase accordingly, further
highlighting the importance of research on PM and FXTAS
(Jacquemont et al., 2004). At the present time there are no
effective treatments to improve neurological function and overall
quality of life for many affected PM carriers and FXTAS patients
(Hagerman et al., 2008, 2009, 2010; Berry-Kravis et al., 2011).
Therefore, it is extremely important to understand the underlying
pathology in FXTAS, establish its developmental time course, and
develop rational treatment strategies.
The goal of this preclinical study was to determine whether
chronic treatment with the neurosteroid Allopregnanolone
(Allop, 3α-hydroxy-5α-pregnan-20-one) would improve motor
function and anxiety-like behaviors in a knock-in mouse model
(i.e., CGGex KI) of the PM and FXTAS (Willemsen et al., 2003;
Van Dam et al., 2005; Berman and Willemsen, 2009). This mouse
KI model recapitulates much of the pathology in the PM and
FXTAS (Berman and Willemsen, 2009). This includes a 2–3-
fold elevation in Fmr1 mRNA in brain and the accumulation
over time of ubiquitin-positive intranuclear inclusions in both
neurons and astrocytes. The KI model also exhibits motor deficits
on the rotarod and ladder walking tasks (Van Dam et al., 2005;
Hunsaker et al., 2011), cognitive impairments in several spatial
memory tasks (Van Dam et al., 2005; Hunsaker et al., 2009),
and increased anxiety in the elevated plus-maze (Berman and
Willemsen, 2009), modeling clinical symptoms often seen in PM
carriers and in patients with FXTAS.
Allop is a neurosteroid that enhances GABAA function,
stimulates neurogenesis and has been shown to improve
cognitive function in animal models of neurodegenerative disease
including Alzheimer’s disease (Brinton and Wang, 2006a,b;
Wang et al., 2010). Allop has also has been found to enhance
adult neurogenesis in the hippocampal subgranular zone (SGZ)
(Genazzani et al., 1998; Kim et al., 2006; Herd et al., 2007; Nilsen
et al., 2007; Wang et al., 2010; Chen et al., 2011; Noorbakhsh
et al., 2011; Turkmen et al., 2011; Holden et al., 2012; Singh et al.,
2012; Sun et al., 2012). Allop appears to stimulate neurogenesis
in the hippocampus through a GABAA mediated increase in
intracellular calcium, leading to increased expression of genes
for proteins that promote cell proliferation (Wang et al., 2005,
2008). This is relevant because GABAergic transmission appears
to be abnormal in CGGex KI mice. D’Hulst et al. (2009) reported
that GABAA receptor subunits, transporters (GAT 1 and 2),
and GAD are upregulated in the cerebellum of CGGex KI mice,
suggesting a compensatory response to decreased GABAergic
transmission. Levels of the GABA vesicular transporter VGAT
are also lower in hippocampal neurons cultured from CGGex KI
mice suggesting reduced presynaptic levels of GABA (Cao et al.,
2012). In addition, reduced GABAergic signaling in cultured
neurons from CGGex KI mice results in burst-firing of neurons
and abnormal patterns of Ca+2 oscillations that can be rescued
by culturing neurons in the presence of Allop (Cao et al.,
2012). Therefore, in this study we examined the ability of Allop
treatment to ameliorate behavioral pathology in a mouse model
of the PM and FXTAS.
A recent open-label study assessed whether Allop given as
12 weekly infusions (2–6 mg) to 6 FXTAS patients would
improve clinical symptoms, brain electrophysiological activity,
and MRI measurements of brain deterioration and white matter
pathology (Wang et al., 2017). Treatment improved executive
functioning, episodic memory and learning, and increased N400
repetition effect amplitude as an index of brain activity. Overall
deterioration of the brain on MRI was not significantly affected,
although some patients showed improvement. In a separate
report in 2019, plasma pharmacometabolomics and lymphocytic
mitochondria function were assessed at baseline and within
48 h from the last infusion, and Allop treatment altered GABA
metabolism and reduced markers of oxidative stress (Napoli et al.,
2019). Considered together, results of this limited pilot clinical
research project indicate that Allop may improve psychological
and cognitive performance in FXTAS, and that further research is
warranted, including preclinical studies such as the present study.
MATERIALS AND METHODS
Animals
Twenty-three male B6.129P2(Cg)-Fmr1tm2Cgr “dutch CGG KI
mice” (CGG KI) aged 13–16 months old, and 18 aged-matched
wild type (WT) littermates were derived from a total of 18 litters
bred at the UC Davis Neurotherapeutics Institute. The range of
CGG trinucleotide repeat expansions for CGG KI mice was 67–
197 (Mean 112 ± 10.5), and 10.0 ± 0.4 for WT mice. The mice
were randomly assigned to receive 10 once-weekly injections
of 10 mg/kg, s.c. Allopregnanalone (Allop) or β-cyclodextrin
vehicle control (Veh) in one of 4 treatment groups: wild type-
vehicle (WT-Veh; n = 9), wild type-Allop (WT-Allop; n = 9),
CGG KI-vehicle (CGG KI-Veh; n = 11), CGG KI-Allop (CGG
KI-Allop; n = 12). This drug injection protocol was patterned
after that reported to improve cognitive performance in a mouse
model of Alzheimer’s disease (Singh et al., 2012), and the Allop
treatment paradigm was designed to avoid the potential cognitive
impairments observed with acute exposure (Johansson et al.,
2002, 2016). In order to avoid any transient effects of Allop
as an acute GABAA receptor modulator, mice were given a 1-
week washout period after the last Allop injection before being
evaluated across a series of behavioral tasks to assess motor
coordination, balance, locomotor activity, and arousal as outlined
in Figure 1. All experiments were conducted during the light
phase of the light/dark cycle and were pre-approved by the
University of California, Davis IACUC and in accordance with
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FIGURE 1 | Timeline for the experimental procedures. WT and CCG KI mice between the ages of 13–16 months old were treated once weekly with
allopregnanolone (Allop) (10 mg/kg s.c.) or β-cyclodextrin vehicle control. Following the last injection, mice were left undisturbed for a 1-week drug washout period
and then assessed for behavioral differences across a battery of motor and arousal tasks. Then, mice were injected once daily with 5-bromo-2′-deoxyuridine (BrdU,
100 mg/kg i.p.) for seven consecutive days and their brains were then processed for evidence of neurogenesis.
the policies of the National Institutes of Health for the humane
care and use of laboratory animals.
Genotyping
CGG repeat length was determined using methods previously
described by Hunsaker et al. (2011). Briefly, DNA was extracted
from mouse tails by incubation with 10 mg/mL Proteinase
K (Roche Diagnostics; Mannheim, Germany) in 300 µL lysis
buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM EDTA,
150 mM NaCl, 1% SDS overnight at 55◦C. One hundred
µL saturated NaCl was then added and the suspension was
centrifuged. One volume of 100% ethanol was added, gently
mixed, and the DNA was pelleted by centrifugation and the
supernatant discarded. The DNA was washed and centrifuged
in 500 µL 70% ethanol and then dissolved in 100 µL milliQ-
H2O. CGG repeat lengths were determined by PCR using the
Expanded High Fidelity Plus PCR System (Roche Diagnostics).
Approximately 500–700 ng of DNA was added to 50 µL of PCR
mixture containing 2.0 µM/L of each primer, 250 µM/L of each
dNTP (Invitrogen; Tigard, OR), 2% dimethyl sulfoxide (Sigma-
Aldrich; St. Louis, MO), 2.5 M Betaine (Sigma-Aldrich), 5 U
Expand HF buffer with Mg (7.5 µM/L). The forward primer
was 5′-GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3′ and
the reverse primer was 5′-AGCCCCGCACTTCCACCACCA
GCTCCTCCA-3′. PCR steps were 10 min denaturation at 95◦C,
followed by 34 cycles of 1 min denaturation at 95◦C, annealing
for 1 min at 65◦C, and elongation for 5 min at 75◦C to end
each cycle. PCR ended with a final elongation step of 10 min
at 75◦C. DNA CGG band sizes were determined by running
DNA samples on a 2.5% agarose gel and staining DNA with
ethidium bromide.
Open Field
Locomotor behaviors were tested by placing mice in an empty
Plexiglas arena (30 cm × 30 cm × 38 cm) and allowing them to
freely explore the environment for 5 min. The total time spent
in the center and margin of the arena as well as the number of
line crosses in a 3 × 3 grid were counted by researchers blind to
genotype and treatment conditions.
Marble Burying
Mice were habituated for 10 min to clean Plexiglas cages (37 cm
× 14 cm × 12.5 cm) filled with a 4 cm thick layer of clean
corncob bedding for 10 min. Following habituation, animals were
returned to their home cage and 15 glass marbles were laid out in
five rows of three marbles placed equidistance apart. Mice were
then returned to the cages and allowed to explore under dim
illumination for 10 min. At the end of the 10 min period, animals
were gently removed from the testing cages and the number of
marbles buried was recorded. Only marbles covered by 75% or
more bedding were counted as buried.
Rotarod
Balance and motor coordination were assessed using a Rotamex-
5 rotarod with infrared photocell detection (Columbus Instr.,
Columbus, OH). Mice were first given an initial training session
by placing them on the rotarod rotating at a constant speed of
4 RPM for 120 sec. Mice that fell were immediately reloaded
and allowed to complete the training session. The following day,
mice were placed on the rotarod at an initial speed of 4 RPM
that accelerated by 1.0 RPM every 10 s. A trial was terminated
when a mouse fell from the rod at which time the latency to fall
was recorded. Each mouse was tested twice. Mean performance
time was defined as the average time the mouse remained on the
rotarod across trials.
Elevated Plus Maze
Anxiety in the mice was assessed using the elevated plus maze
(Handley and Mithani, 1984; Walf and Frye, 2007). The Plexiglas
apparatus consisted of two open arms (30 cm × 5 cm × 0.5 cm)
and two perpendicular closed arms (30 cm × 5 cm × 15 cm)
extending from a central platform. The entire maze was elevated
approximately 1 m from the floor. Mice were placed in the central
platform and allowed to freely explore the maze for 5 min. The
total number of entries in the open arm, as defined by all four
paws outside the central zone, as well as the total time spent in
the open and closed arms were recorded. Percent of open arm
exploration time was calculated as the time in the open arm
divided by the total time in both the open and closed arms.
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Ladder Walk
The ladder walk task was conducted as previously described
(Hunsaker et al., 2011). The apparatus consisted of two, 28 cm
tall × 65 cm long black walls separated by 10 cm. The floor
was elevated 10 cm from the bottom of the walls and was made
from 43 parallel 1 mm diameter bars separated by 1.5 cm. Mice
were placed in the apparatus and allowed to freely explore the
apparatus for 2 min while being video recorded. The digital
recordings were scored for the number of times a foot (forelimb
or hindlimb) slipped through the floor bars as previously
described (Hunsaker et al., 2011). The digital recordings were
scored independently by two experimenters blinded to the
genotype and treatment of the animals.
Histology
Immediately following the final behavioral task, mice were
injected once daily with 5-bromo-2′-deoxyuridine (BrdU)
(100 mg/kg, i.p.) for seven consecutive days and then sacrificed
to quantify hippocampal neurogenesis as previously described
(Wojtowicz and Kee, 2006). Briefly, brain tissue was fixed with
4% paraformaldehyde, flash frozen, and serial 40 µm sections
were cut anterior-posterior through the hippocampus. Sections
were mounted on glass slides, rinsed 3 times for 10 min each
with 0.1 M phosphate buffered saline (PBS) followed by 0.5%
hydrogen peroxide in methanol for 15 min. Following another
series of rinses, sections were submerged in 2N HCL solution for
20 min at 37 degrees Celsius, rinsed 3 times for 10 min each,
and placed in blocking solution of 3% BSA, 3% goat serum, and
0.3% triton X for 1 h. Sections were then incubated for 18 h in
blocking solution containing 1:50 anti-BrdU antibody (Accurate
Chemical) and 1:100 anti-NeuN (EMD Millipore). The following
day, sections were rinsed 6 times for 5 min each with 0.1 M
PBS containing 0.3% Triton X and then incubated in blocking
solution containing fluorescent-labeled secondary antibodies for
2 h. Sections were counter stained in a 1:500 solution of DAPI,
rinsed 6 times for 5 min. each in 0.1 M PBS, and coverslipped
with fluoromount G. The number of BrdU+ and double labeled
BrdU+/NeuN+ cells were quantified in the subgranular zone
of the dentate gyrus, defined as a narrow band 1–2 cells thick
between the granule cell layer and the hilus (Kempermann et al.,
1997), on every fifth section. Co-localization was determined by
focusing through each section and toggling between filter sets to
visually establish that immunofluorescence for BrdU and NeuN
was from the same cell.
Statistical Analysis
Data were analyzed using R version 4.0.4 (2021) using the “stats”
and “pscl” packages. Mortality measures (i.e., number of deceased
mice throughout the study) were evaluated across genotype and
treatment conditions using chi-square test for independence.
For behavioral measures, assumptions of normality and linearity
were evaluated using the Shapiro-Wilks test and assessed visually
using qqplots and histograms. Count data (number of open
arm entries, marble burying, and ladder walk slips, and cell
counts) containing excess numbers of zeros were assessed using
Zero-Inflated Poisson regression followed by post hoc planned
comparisons. Similarly for continuous measures (open field,
rotarod), data were analyzed using Wilcoxon-Mann-Whitney
planned comparisons to determine if (1) wild type mice treated
with vehicle (WT-Veh) differed significantly from vehicle-treated
CGG KI mice (CGG KI-Veh); (2) CGG KI mice treated
with Allop (CGG KI-Allop) differed significantly from CGG
KI-Veh mice; and (3) if wild type mice treated with Allop
(WT-Allop) differed significantly from WT-Veh. All analyses
were two-tailed, and values of p ≤ 0.05 were considered
statistically significant. All graphs show sample medians and
inter-quartile range (IQR).
RESULTS
Mortality and Body Weight
A total of 4 CGG KI mice and 2 wild type mice died during the
time-course of the study. Of those deceased, 1 CGG KI vehicle-
injected and 2 wild type Allop-injected mice were euthanized
before the end of the injection series due to skin lesions at
the site of the subcutaneous injections (Table 1). Chi-square
analysis confirmed that there were no differences in the number
of mice that died or were euthanized between genotype [X2 (1,
N = 41) = 0.81, p = 0.37] or drug treatment, [X2 (1, N = 41) = 0.04,
p = 0.84]. There were no significant differences in body weight
among groups before or after the last injection of either saline or
Allop, and no significant change in body weight between the 1st
and 10th injection due to treatment or genotype.
Locomotor Activity and Arousal
Locomotor and anxiety-related behaviors for CGG KI and wild
type mice were measured in the open field and elevated plus
maze tasks (Figures 2A–D). Overall activity in the open field was
quantified by the number of line crosses over a 5 min period.
As shown in Figure 2A, CGG KI-Veh mice had significantly
fewer line crosses (i.e., lower activity) compared to WT-Veh mice,
and this effect was ameliorated in the CGG KI mice by Allop
treatment. Statistical analysis of locomotor activity in the open
field, measured by the number of line crosses, confirmed that
activity was significantly lower in CGG-Veh mice compared to
WT-Veh mice (p = 0.018). Allop treatment did not significantly
affect Wild type mice (i.e., WT-Veh vs. WT-Allop, p = 0.790), but
significantly increased activity in the CGG KI mice (CGG KI-Veh
vs. CGG KI-Allop, p = 0.007). In fact, Allop treatment restored
locomotor activity in the CGG KI mouse to a level similar to
vehicle-treated wild type mice.
As shown in Figure 2B, there was a significant effect of
Allop treatment on time spent in the margin for CGG KI mice.
TABLE 1 | Sample sizes for each genotype and treatment group.
Genotype Treatment Alive Deceased
Wild type Vehicle 9 0
Wild type Allop 7 2
CGG repeat Vehicle 9 2
CGG repeat Allop 10 2
There were no significant differences in the number of mice that died or were
euthanized between groups.
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FIGURE 2 | Locomotor activity, arousal, and anxiety-associated behaviors in the CGG KI and wild type mice. Mice were treated for 10 weeks with Allop or vehicle
control and evaluated for locomotor activity and thigmotaxis in the open field task (A,B), anxiety-like measures in the elevated plus maze (C,D), and repetitive digging
behavior in the marble burying task (E). Reported are (A) the number of lines crossed during a 5-min open field exploration; (B) the total time spent exploring the
margins of the open field arena (i.e., thigmotaxis); (C) the percent time exploring the open arms in the elevated plus maze, as well as (D) the total number of entries
into the open arms; (E) the percent of marbles buried in the marble burying task. *p < 0.05 as determined by Wilcoxon-Mann-Whitney (Locomotor Activity and
Thigmotaxis) or Zero-Inflated Poisson Regression (Elevated Plus Maze and Marble Burying) followed by pairwise planned comparisons. Plots represent individual
mice; bars represent median ± IQR. Wild type-vehicle (n = 9), wild type-Allop (n = 7), CGG KI-vehicle (n = 8), CGG KI-Allop (n = 10).
Planned comparisons showed that WT-Veh mice did not differ
significantly in margin time from either WT-Allop (p = 0.831)
or CGG KI-Veh (p = 0.699). However, CGG KI-Allop treated
mice spent less time in the margin compared to CGG KI-Veh
(p = 0.050).
In the elevated plus maze, there was no difference in percent
time in the open arms between vehicle treated mice of both
genotypes (p = 0.918) and no effect of treatment on CGG KI-
Allop (p = 0.133) or WT-Veh (p = 0.491). On average, mice
only spent approximately 24% of their exploration time in the
open arms of the maze (Figure 2C). Importantly, there were
no differences in the total number of open arm entries between
genotypes (z = 0.04, p = 0.631) or treatment (z = 0.02, p = 0.851),
suggesting that motor activity did not impact elevated plus maze
performance (Figure 2D).
Figure 2E shows the results of Allop treatment on marble
burying used as a test of repetitive digging behavior (Thomas
et al., 2009). There was a significant treatment by genotype
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interaction (z = 2.26, p = 0.024), in the number of marbles
buried in a 10-min marble burying task. Planned comparisons
confirmed that CGG KI-Veh mice buried fewer marbles
than WT-Veh and CGG KI-Allop mice (p < 0.001 for
both comparisons).
Motor Coordination
Motor coordination was evaluated in the rotarod (Figure 3A) and
ladder walk tasks (Figure 3B). In the rotarod task, there were no
differences in total time on the rotarod between genotypes, WT-
Veh compared to CGG KI-Veh (p = 0.630), and no differences
between treatment conditions, CGG KI-Veh compared to CGG
KI-Allop (p = 0.897) and WT-Veh compared to WT-Allop
(p = 0.536). On the ladder walk test, a poisson regression
revealed a marginally significant effect of treatment (z = 1.93,
p = 0.053) based on genotype (z = 2.08, p = 0.038). Specifically,
Allop treatment in WT mice reduced the number of foot slips
compared to WT-Veh controls (p = 0.051), but no differences
were observed between Allop and Vehicle treatment in CGG KI
mice (p = 0.425) (Figure 3B).
Dentate Gyrus Neurogenesis
The effects of 10 weeks of once weekly Allop treatment on cell
proliferation and neurogenesis in the hippocampus are shown in
Figure 4. Images of the dentate gyrus labeled with BrdU (green
fluorescence, Figure 4A) and NeuN (red fluorescence, Figure 4B)
were quantified for the number of colocalized BrdU+/NeuN+
cells (yellow fluorescent cells; see insert, Figure 4C). Poisson
regression analysis for the total number of BrdU+ cells confirmed
a significant treatment effect of Allop (z = −8.42, p < 0.001)
but not for genotype (z = −1.42, p = 0.157). Figure 4D shows
a greater number of BrdU+ cells in both WT-Allop (p = 0.003)
and CGG KI-Allop (p < 0.001) compared to genotype-matched
vehicle controls. There was no significant effect of genotype
on the total number of BrdU+/NeuN+ double-labeled cells in
the dentate gyrus (Figure 4E), classified as adult proliferating
neurons (i.e., adult neurogenesis), and the effect of AlloP
treatment on BrdU+/NeuN+ double-labeled cells did not reach
statistical significance (z = −1.67, p = 0.095). However, there
was a significant treatment by genotype interaction (z = 2.46,
p = 0.014). Planned comparisons confirmed a small increase in
the number of double-labeled BrdU+/NeuN+ cells in CGG KI-
Allop mice compared to genotype-matched CGG KI-Veh mice
(p = 0.024). Figure 4F shows the total number of cells that labeled
for BrdU, but not NeuN (BrdU+/NeuN−), calculated as the
difference between total BrdU+ cells labeled and BrdU+/NeuN+
double labeled cells. This population of BrdU labeled cells likely
includes proliferating astrocytes, oligodendrocytes and microglia,
as well as young neurons not expressing NeuN although they
were not further classified in this study. Interestingly, there was
a significant effect of treatment on the number of non-neuronal
BrdU+/NeuN− cells (z = −8.57, p < 0.001). Planned group
comparisons showed the number of BrdU+/NeuN− cells was
significantly larger in the CGG KI-Allop mice compared to the
CGG KI-Veh mice (p < 0.001), and in the WT-Allop mice
compared to genotype-matched WT-Veh controls (p < 0.001).
No effect of genotype were observed between WT-Veh mice and
CGG KI-Veh groups (p = 0.923).
DISCUSSION
The CGG KI mouse is a well-validated and established
pre-clinical tool for modeling the hallmark behavioral and
neurobiological features of the Fragile X PM and FXTAS.
This includes motor dysfunction, ubiquitin-positive inclusions,
and disruptions in GABAergic signaling (Brouwer et al., 2008;
D’Hulst et al., 2009; Berman et al., 2014). While treatments for
FXTAS are, to date, only palliative, it has been hypothesized
that pharmacological agents that target the GABAergic system
may improve neurological function or delay disease progression.
In particular, Allop has undergone an initial open-label clinical
trial to test its efficacy in reversing the motor and cognitive
deficits in a small population of elderly men with FXTAS (Wang
et al., 2017; Napoli et al., 2019). Given the high degree of
construct validity observed in the CGG KI mouse, we tested
whether a similar regimen of Allop in aged CGG KI mice would
show efficacy in reducing the behavioral pathologies observed in
this mutant mouse model. Our results demonstrated significant
improvements in locomotor activity in the open field, but
without concomitant improvements in coordination and balance
in the rotarod or ladder walk tests. Together, these data provide
additional evidence supporting a potential therapeutic effect of
Allop on specific FXTAS-associated behavioral deficits.
In humans, premutation carriers show longer, slower motor
movements and reaction times that worsen with age (Shickman
et al., 2018). Our aged CGG KI mice showed similar deficits in
locomotor activity and arousal given the observed reductions in
line crosses in the open field task and reduced marble burying
activity. The marble burying task in particular revealed a near
absence of buried marbles in the CGG KI-Veh mice, likely due
to deficits in motor activity and general arousal as a result of the
insertion of the CGG-repeat. Treatment with Allop for 10 weeks
restored these deficits in motor activity and arousal in both
the marble burying and open field tasks to levels observed in
wild type controls. These convergent phenotypes across multiple
behavioral assays (i.e., open field and marble burying) serve as
a measure of reliability in Allop’s restorative effects on motor
activity. Interestingly, 10 weeks of Allop treatment did not
further enhance arousal levels in wild type mice, underscoring
the specificity of targeting GABAergic systems to restore, but
not enhance, locomotor activity. While these improvements in
motor activity would suggest a therapeutic potential for Allop,
similar restorative responses were not observed in measures of
anxiety, namely the elevated plus maze and thigmotaxis (time
in center) measures in the open field arena. Performance on
the elevated plus maze task declines with age in the C57BL/6
mouse strain, with aged-mice exhibiting fewer entries and
reduced time in open-arm exploration (Sukoff Rizzo et al.,
2018; Shoji and Miyakawa, 2019). Similar to our observations
in the rotarod and ladder rung task, our observed similarities
in elevated plus-maze performance between aged wild type and
CGG KI mice would suggest that natural age-related declines
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FIGURE 3 | Behavioral assessments of balance and motor coordination in response to Allop in the wild type and CGG KI mouse. Following 10 weeks of Allop
treatment mice were evaluated for changes in balance on the rotarod task and motor coordination in the ladder rung task. (A) No differences were observed in the
average time to fall in the rotarod task. (B) In the ladder rung task, mice were evaluated for total number of slips. *p < 0.05 as deteremined by
Wilcoxon-Mann-Whitney (Rotarod) or Poisson Regression (Ladder Walk) followed by pairwise planned comparisons. Plots represent individual mice; bars represent
median ± IQR. Wild type-vehicle (n = 9), wild type-Allop (n = 7), CGG KI-vehicle (n = 8), CGG KI-Allop (n = 10).
FIGURE 4 | Hippocampal cell proliferation and adult neurogenesis in the brains of CGG KI and wild type mice. Fluorescent photomicrographs of (A) BrdU+ cells
(green fluorescence) in the subgranular zone of the hippocampus. (B) Neurons were labeled with NeuN (red fluorescence), and (C) newly generated neurons are
co-labled BrdU+/NeuN+ and appear yellow (high magnification insert). Images shown at 20x magnification. (D) The total number of BrdU+ cells in the subgranular
zone of WT and CGG KI mice treated with Allop or vehicle for 10 weeks. (E) The total number of double labeled BrdU+/NeuN+ cells reflecting adult neurogenesis in
the dentate gyrus of the hippocampus. (F) The number of new cells not labeled with NeuN (BrdU+/NeuN−) was calculated as the total number of number of BrdU+
cells in (D) minus the total number of BrdU+/NeuN+ in (E). *p < 0.05 as determined by poisson regression (BrdU+ and BrdU+/NeuN−) or zero-inflated poisson
regression (double-labeled BrdU+/NeuN+) analysis followed by pairwise planned comparisons. Plots represent aggregated count data of individual mice; bars
represent median + IQR. Wild type-vehicle (n = 5), wild type-Allop (n = 6), CGG KI-vehicle (n = 7), CGG KI-Allop (n = 10). BrdU, 5-bromo-2′-deoxyuridine.
in performance may be masking earlier anxiety-like effects of
the CGG premutation reported in younger CGG KI mice.
Therefore, the potential therapeutic effects of Allop treatment
on anxiety-like measures remain inconclusive given our inability
to effectively evaluate premutation-induced changes in elevated
plus-maze performance.
Motor coordination, ataxia and balance are among the
hallmark symptoms of FXTAS, and the CGG KI mouse
is characterized to show similar deficits in movement and
coordination including increases in foot slips in the ladder
rung task (Hunsaker et al., 2011) and changes in rotarod
performance (Van Dam et al., 2005). Unexpectedly, we did
not observe these differences in motor function between our
aged wild type and CGG KI mice in either test, regardless of
Allop treatment. These results are similar to the study by Van
Dam et al. (2005) who also found that rotarod performance
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did not differ significantly between 20-, 52-, and 72-week-
old CGG KI and control mice. Only when genotypes were
analyzed separately did they observe evidence of a significant age-
related decline in rotarod performance in 52- and 72-week-old
CGG mice compared to 20-week-old genotype-matched mice.
While procedural differences between the present study and
that of Van Dam et al. (2005) make it difficult to compare
studies, such as rotarod apparatus (i.e., Rotamex 5 vs. Ugobasile),
pretesting adaptation trials (i.e., a single vs. 2 min trials) and
time between adaptation and testing (i.e., 24 h vs. immediate),
it is clear that aged CGG KI and control mice did not
differ significantly in either study. Previous studies have used
a combination of young and old-aged mice (4–16 months)
(Hunsaker et al., 2011; Wenzel et al., 2019), but the behavioral
phenotype of CGG KI mice at advanced ages, such as the mice
used in the present study, has not been well characterized.
This is important given that C57BL/6 mice exhibit age-related
changes in behaviors including increased anxiety and decreases
in motor performance (Sukoff Rizzo et al., 2018; Shoji and
Miyakawa, 2019). As a result, natural age-related declines in
wild type mouse motor performance (e.g., rotarod and ladder
rung test) may equal declines in the aged CGG KI mice,
thereby masking differences between wild type and KI mice
previously reported in younger mice. Moreover, Allop did not
alter rotarod motor performance in either wild type or CGG
KI groups, suggesting that weekly treatment with Allop does
not improve motor function when started at an advanced age.
In a recent pilot study of 6 individuals with FXTAS, 12-weeks
Allop did not improve tremor or ataxia (Napoli et al., 2019)
corroborating our preclinical findings in the CGG KI mouse.
As a result, our data would suggest that targeting GABAergic
function with weekly Allop treatment is not sufficient to restore
motor coordination deficits resulting from age-related declines
in motor function. However, it remains unexplored whether
treatment at an earlier age could mitigate or delay the onset
of pathology in premutation carriers before the full onset of
FXTAS symptomatology.
Allop is an active metabolite of the naturally occurring
neurosteroid progesterone with numerous actions in the central
nervous system. Allop and other neurosteroids exert numerous
classic and non-classic actions in the central nervous system,
including promoting genomic and non-genomic cell-cycle
functions modulating cell proliferation, cell shape, and gene
expression (Garcia-Segura et al., 1996, 1999; Jordan, 1999;
Nichols, 1999). Previous studies have demonstrated Allop’s ability
to promote adult glial cell health and proliferation in addition to
its effects on neurogenesis (for review see Faroni and Magnaghi,
2011). Allop is also an allosteric modifier of the GABAA
receptor and can stimulate neurogenesis in the hippocampus
(Baulieu et al., 2001). Given the known proliferative effects of
Allop on hippocampal neurogenesis both in vitro (Wang et al.,
2005) and in vivo (Wang et al., 2010), we examined whether
the locomotor and arousal improvements we observed in our
CGG KI mice were accompanied by concomitant increases in
adult neurogenesis in the dentate gyrus. Adult hippocampal
neurogenesis has been demonstrated in all mammalian species
studied to date including mouse (Kempermann et al., 1997;
Zhao et al., 2006), rat (Kuhn et al., 1996), non-human primate
(Gould et al., 1999) and human (Eriksson et al., 1998). The
function of adult neurogenesis is still unclear, but a growing
body of evidence indicates its importance in processing of
sensory stimuli such as spatial cues necessary for behavioral
discrimination (Tuncdemir et al., 2019). Ten weeks of treatment
with Allop did not provide compelling evidence of increased
neurogenesis in either aged wild type or CGG KI mice. However,
this observation is tempered by the fact that in the present study
group sizes were relatively small, and numbers of proliferating
neurons in the dentate gyrus were also comparatively small,
possibly due to the advanced age of the mice used in this study.
Adult neurogenesis in the hippocampus declines with age in mice
(Kempermann et al., 2002; Yang et al., 2015) and rats (Kuhn
et al., 1996), although stable levels of human hippocampal adult
neurogenesis have been reported throughout aging (Boldrini
et al., 2018). Therefore, the potential for Allop to stimulate
adult neurogenesis in the aged rodent hippocampus may be
somewhat limited, making it more difficult to document potential
drug effects on neurogenesis. It is also possible that the dosage
or timing of injections were insufficient to stimulate neuronal
proliferation in aged mice.
Ten weeks of Allop injections did significantly increase the
total numbers of BrdU-labeled cells that were not NeuN+ in
both wild type and CGG KI dentate gyrus. The identity of
these proliferating cells was not further examined in the present
study, and will need to be determined in future studies. One
plausible explanation for this low level of BrdU+/NeuN+ double
labeling may be a result of the timing of BrdU injections
and time of sacrifice before histological evaluation. Specifically,
Snyder et al. (2009) found that newly generated neurons do
not express NeuN until 2–3-weeks after birth, a time period
longer than used in the present study. Although we adopted
a substantially different BrdU injection regimen to Snyder
et al. (2009), their results open the possibility that many of
the BrdU+ only cells in our AlloP-exposed mice may include
immature neurons not yet expressing the NeuN neuronal
marker (Snyder et al., 2009). If so, it is possible that the
increase in BrdU+ cells (Figure 4D) included new neurons
stimulated by AlloP treatment but not yet expressing NeuN.
Alternatively, total number of BrdU+ cells in 4D includes
astrocytes, oligodendrocyte precursor cells, oligodendrocytes and
microglia. Gliogenesis in the adult mammalian hippocampus
is well documented (Rietze et al., 2000; Wang et al., 2005;
Nixon et al., 2008), and in a triple transgenic mouse model
of Alzheimer’s disease (3xTgAD), chronic Allop treatment
promoted not only neurogenesis, but oligodendrogenesis (Irwin
and Brinton, 2014; Chen et al., 2020). It is notable that this
increased proliferation of BrdU+ cells by Allop treatment was
observed across wild type and CGG KI hippocampus, although
planned comparisons indicated that the effect was mainly due
to the drug’s effects in the CGG KI mouse hippocampus. Glia
constitute roughly half of the cells of the central nervous system
and provide important functions including homeostasis, neural
development, migration, synaptogenesis, synaptic transmission
and neural plasticity (Allen and Lyons, 2018). In view of the
importance of glia for CNS function, and the possible occurrence
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of non-cell autonomous pathology from glial to neurons in
FXTAS (Wenzel et al., 2019), it is possible that proliferation
of one or more glial subtypes may have contributed to the
behavioral results of the present study and this should be
examined in future studies.
Considered together, our data provide evidence that 10 weeks
of Allop treatment in aged-CGG KI mice improves deficits in
locomotor activity and repetitive digging behavior in the marble
burying test. Several behavioral measures evaluated in these aged
mice, including rotarod and ladder walk, did not show differences
between CGG KI and wild type controls in contrast to what has
been reported in young CGG KI mice (Berman et al., 2014).
This prevents the drawing of any conclusions about possible
Allop effects on these types of behaviors. One possibility is that
age-related declines in motor performance in very old wild type
C57 mice may reach the same level as that of CGG KI mice,
making it difficult to compare and identify impaired motor
performance in aged CGG KI mice. Given the myriad effects of
Allop in modulating both cellular and neurochemical systems
in the central nervous system, it is important in the future to
examine whether treatment with Allop in earlier stages of the
PM pathology may be more effective in delaying the onset of
the behavioral and histopathological deficits induced by the CGG
repeat expansion.
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